企業プロフィール
HUTCHMED 株価・ニュース・カタリスト
- ティッカー:
- HCM
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- China and listed in the U
株価パフォーマンス
12.56 USD (+2.95%)
終値
最終更新: 2026年8月17日
1.98B USD
時価総額
株価変動の要因
Following the latest company update, “HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EG…”, HCM closed up 2.95% at $12.56 on Aug 17, 2026. The move occurred in the trading session associated with this clinical readout update.
企業概要
China-Originated Oncology Company
HUTCHMED is an oncology-focused biopharmaceutical company with commercial products in China and partnered global products. Its strategy combines China commercialization, global partnerships, and internal R&D aimed at differentiated small molecules and newer antibody-targeted modalities.
Commercial Oncology Portfolio
The company's commercial base includes ELUNATE, SULANDA, FRUZAQLA, ORPATHYS, and other oncology products. First-half 2026 growth was led by a rebound in China product sales and geographic expansion of FRUZAQLA outside China, which had approvals or launches in 41 countries.
Late-Stage Regulatory Pipeline
HUTCHMED has multiple late-stage programs across oncology and immunology. Recent progress includes China approval of ELUNATE with sintilimab for second-line kidney cancer, China NDA acceptances for sovleplenib in wAIHA and ITP, ORPATHYS approval in third-line MET-amplified gastric cancer, and positive data for fanregratinib in FGFR2 fusion or rearrangement intrahepatic cholangiocarcinoma.
ATTC Innovation Strategy
The company is investing in antibody-targeted therapy conjugates, or ATTCs, that use antibody targeting to deliver potent small-molecule payloads to tumor cells. HMPL-A251, HMPL-A580, and HMPL-A830 represent a newer platform layer intended to create first-in-class or best-in-class candidates and support multinational partnering opportunities.
今後のカタリスト
- Topline results from SAFFRON and SANOVO Phase 3 savolitinib studies in the second half of 2026.
- NMPA review of sovleplenib in wAIHA and ITP.
- Global clinical trial initiation for HMPL-A830 in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。